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Background: We sought to determine whether oral secretions could be used as a surro-
gate for cervical secretions for monitoring cervical immunoglobulin (Ig) levels.To do so, we
examined (1) whether oral IgG and IgA levels correlated with those observed at the cervix,
and (2) whether time of menstrual cycle and other factors previously reported to influence
cervical Ig levels were associated with oral IgG and IgA levels. Methods: We obtained oral
samples from a group of 85 Costa Rican woman 25–35 years of age measured at three
time points during one menstrual cycle.Total IgG and IgA levels were measured by ELISA.
Generalized estimating equations methods that account for repeated measures were used
to evaluate the association between oral and cervical Ig levels and to evaluate the associ-
ation between various covariates and oral IgA and IgG levels. Results: We did not observe
an association between oral and cervical IgG [linear regression coefficient (LRC) 0.01; 95%
CI, −0.05 to 0.07] and IgA levels (LRC 0.02; 95% CI, −0.04 to 0.08). Oral IgG and IgA
levels were not influenced by phase of menstrual cycle, in contrast to what has previously
been observed for cervical Ig levels. Conclusion: Our data suggest that oral IgG and IgA
measures are not a good surrogate for cervical IgG and IgA levels. Future studies should
examine whether antigen-specific antibody responses induced by vaccination correlate
across mucosal sites.
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INTRODUCTION
During the past decade, oral sampling has gained increased atten-
tion as an alternative to plasma in monitoring immunity in epi-
demiological studies. Oral sampling has a number of advantages
when compared to venipuncture, including the fact that sampling
is simple, non-invasive, painless, and allows for self-collection
(Wade and Haegele, 1991; Kirschbaum and Hellhammer, 1994).
Many biomarkers have been evaluated in oral secretions including
hormones (Riad-Fahmy et al., 1982; Wade and Haegele, 1991),
vaccine-induced antibodies (Kozlowski et al., 1999; Rowhani-
Rahbar et al., 2009), and cytokines (Streckfus et al., 2002). This
makes oral secretions a relevant source for monitoring hormone
levels and antibody responses in vaccinated individuals. We were
interested in determining whether oral immunoglobulin (Ig) lev-
els represent a good surrogate for cervical mucosal Ig levels.
This is of particular relevance for monitoring recipients of the
recently licensed prophylactic HPV vaccines (Muñoz et al., 2009;
Paavonen et al., 2009). The new HPV vaccines induce a strong
antibody response that is believed to be responsible for the protec-
tion against vaccine-related type infections. Because vaccination is
administered systemically whereas protection occurs locally at the
genital tract mucosa, we have had an interest in better understand-
ing the patterns of both systemic and local immune responses and
their interrelationship.
We and others have shown that Ig levels in cervical secretions
may be hormonally influenced, as reflected by fluctuations in cer-
vical IgG and IgA during the menstrual cycle, with levels being
lowest around ovulation and higher in the follicular and luteal
phases of the cycle (Nardelli-Haefliger et al., 2003; Safaeian et al.,
2009a). In contrast, systemic Ig levels have been shown not to be
affected by the menstrual cycle and do not correlate with cervical
Ig levels (Safaeian et al., 2009b).
It is still unknown whether oral levels of Ig reflect those at
the cervix. To determine whether oral secretions can be used as
an alternative to cervical secretions to monitor local Ig levels, we
examined (1) the association between oral and cervical Ig (both
IgG and IgA) levels, and (2) the determinants of total oral IgG and
IgA levels to see whether they are similar to those observed at the
cervix.
MATERIALS AND METHODS
POPULATION
To evaluate mucosal and systemic levels of total IgG and IgA over
the menstrual cycle, a subset of young adult women from Costa
Rica who were participants in a NCI-sponsored study designed to
examine the natural history of HPV infection and cervical intraep-
ithelial neoplasia (Herrero et al., 1997) were contacted if they were
25–35 years old, had no evidence of high-grade cervical lesions,
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were not pregnant, and had an intact uterus. The details of this
study have been described previously (Safaeian et al., 2009a). In
brief, a total of 202 women were invited to participate and asked to
agree to an interview and the collection of cervical and oral secre-
tions (blood was also collected and results reported previously;
Safaeian et al., 2009b) at three time points during one menstrual
cycle within the following time frames: visit 1 (follicular phase)
5–8 days after cycle onset, visit 2 (periovulatory phase) 14–16 days
after cycle onset, and visit 3 (luteal phase) 19–22 days after cycle
onset. After excluding women who were pregnant (n= 3), cur-
rently breast-feeding (n= 17), or had menstrual cycles that were
either too short (<25 days) or too long (>36 days; n= 28), we
selected for study a subset of 104 women, 20 of whom were oral
contraceptive users (the remaining were naturally cycling). For
the present analysis, we further excluded women who did not
provide specimens at all three visits (n= 1), whose oral sponge
weight was unusually low (lower than the mean weight of dry
sponges; n= 4), whose cervical sponge weight was unusually low
(n= 13), and whose cervical IgG and IgA levels were considered
to be outliers (n= 1). A total of 85 women were included in the
final analysis. All participants signed an informed consent, and
the study was approved by the ethical committees at the National
Cancer Institute, USA and INCIENSA, Costa Rica.
SAMPLE COLLECTION AND EXTRACTION
Oral samples were collected using the cellulose-based Ultracell
sponges by holding a sponge on the inner cheek for 15 s and turn-
ing it over to collect oral secretions for another 15 s on the opposite
cheek. Collection of cervical secretions has been described previ-
ously (Kemp et al., 2008; Safaeian et al., 2009a). Following collec-
tion, the sponges (both oral and cervical) were immediately stored
in liquid nitrogen. The secretions were extracted from Ultra-
cell sponges according to the following protocol. Three hundred
microliter of extraction buffer (PBS, Invitrogen, Grand Island, NY,
USA; 1.5% NaCl, Sigma-Aldrich, St. Louis, MO, USA; 100µg/ml
Aprotinin, Sigma-Aldrich; 150 ng/ml mouse IgG1, extraction con-
trol, BD Biosciences, San Jose, CA, USA) was added to the top of
each sponge. The sponges were incubated at 4˚C for 30 min prior
to centrifugation at 13,000× g for 15 min at 4˚C. An additional
300µl of extraction buffer (sans extraction control) was added to
each sponge and immediately centrifuged. Prior to adding 4µl
of fetal calf serum for storage, 20µl of extract was saved for
protein analysis, and 5µl was tested for presence of hemoglobin
(Hemastix, Bayer, Elkhart, IN, USA).
DETERMINATION OF IMMUNOGLOBULIN LEVELS
Total human IgG, human IgA, and extraction control (mouse
IgG1) were measured in duplicate using an ELISA according to
the manufacturer’s protocol (Bethyl Laboratories, Montgomery,
TX, USA). In order to account for variations in the amount of oral
secretion collected between participants, the antibody levels were
standardized based on the following formula: [specimen weight
(g)−mean dry sponge weight (g)+ 0.6 (g)]/[specimen weight
(g)−mean dry sponge weight]; 0.6 (g) refers to the weight of
the extraction buffer added to each specimen. Furthermore, we
added a standardized amount of mouse IgG1 to the extraction
buffer in order to monitor extraction efficiency. The median per-
cent recovery was 75.5% (IQR: 62.7–87.1%). Results from analyses
that evaluated standardized oral Ig levels corrected for percent
recovery did not differ from those obtained using the uncorrected
standardized oral Ig levels except for the correlation between oral
IgA levels amongst smoking status [linear regression coefficient
(LRC) 0.47; 95% CI (0.02–0.92); p= 0.04; data not shown].
STATISTICAL ANALYSES
The IgG and IgA levels were normalized by log transformation.
Geometric mean titers (GMT) of oral IgG and IgA were com-
puted and reported by categories of the covariates examined. Our
main objective was to examine the association of oral IgG and
IgA levels with cervical IgG and IgA, respectively. Other variables
considered as potential confounders were: menstrual cycle phase
(follicular, periovulatory, and luteal), oral contraceptive use (cur-
rent versus not), age (25–29, 30–32, and 33–35 years), smoking
(current versus not), cervical HPV infection (current versus not),
acute illness (current versus not), parity (0, 1–3, and ≥4), saliva
sponge weight (<0.21 versus >0.21 g), and presence of hemoglo-
bin (negative, trace, and positive). The Kruskal–Wallis test was
used to assess significant changes in oral IgG and IgA levels during
the three menstrual cycle phases. Because we had three obser-
vations for each participant, we applied generalized estimating
equations (GEE) models for correlated data to determine which
factors were associated with oral IgG and IgA levels. Robust meth-
ods for linear regression with unstructured correlation structure
were used to estimate standard errors and coefficients adjusted
for multiple observations for each participant. A p< 0.05 is con-
sidered significant. LRC and associated 95% confidence intervals
(CI) are presented. Analysis was performed with STATA 9.2 (Stat-
aCorp LP, College Station, TX, USA), SAS 9.3, and JMP 7 statistical
programs (SAS Institute Inc., Cary, NC, USA).
FIGURE 1 | Association of oral IgG to oral IgA levels. Oral samples
collected from the three phases of the menstrual cycle from 85 participants
were measured for IgG and IgA levels. The graph represents a scatter plot
of untransformed levels of oral IgG and IgA from all three phases of the
menstrual cycle from each participant, and a p-value <0.05 was considered
significant. LRC, Linear Regression Coefficient.
Frontiers in Oncology | Cancer Epidemiology and Prevention June 2012 | Volume 2 | Article 61 | 2
Kemp et al. Determinants of oral IgG and IgA levels
RESULTS
A total of 85 women were included in this analysis. Each woman
was sampled at three time points during a single menstrual cycle
for a total of 255 oral samples with matching cervical samples. The
overall geometric mean concentration of oral IgG and IgA from
the 255 samples was 19.6 and 101µg/ml, respectively. The levels
of total IgG in oral samples were 30-fold lower than the IgG levels
found in the cervix (GMT for cervical IgG= 567µg/ml), and the
levels of IgA in oral samples were 2.5-fold lower than the levels
of IgA detected in the cervix (GMT for cervical IgA= 269µg/ml).
FIGURE 2 | Distribution of oral IgG and IgA levels during the three
phases (follicular, periovulatory, and luteal) of the menstrual cycle overall
(A) and stratified by oral contraceptive (OC) use (B,C). The levels of IgG
and IgA presented in the graphs is based on untransformed values. The
p-value is calculated based on Kruskal–Wallis test, and a p-value <0.05 is
considered significant. GMT, Geometric mean (µg/ml).
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Oral IgG levels were significantly associated with oral IgA levels
from the 255 samples considered as a whole (LRC: 1.82; 95% CI,
1.70–1.96; Figure 1).
Because, we previously reported that cervical levels of IgG
and IgA were significantly lower during the periovulatory
phase of the menstrual cycle among naturally cycling women
(Safaeian et al., 2009a), we examined whether the menstrual
cycle affected oral IgG and IgA levels. In contrast to what we
reported previously at the cervix, we observed no significant
change in oral levels of IgG (p= 0.1) or IgA (p= 0.2) between
phase of menstrual cycle (Figure 2). This was true overall
(Figure 2A) and in analysis stratified by oral contraceptive use
(Figures 2B,C).
Figure 3A depicts the association between oral IgG and cervical
IgG from the 255 samples considered as a whole regardless of the
phase of the menstrual cycle. Oral IgG levels were not associated
with cervical IgG levels (LRC: 0.01; 95% CI,−0.05 to 0.07). Sim-
ilarly as depicted in Figure 3B, oral IgA levels were not associated
with cervical IgA levels (LRC: 0.02; 95% CI,−0.04 to 0.08).
When other potential determinants of oral IgG and IgA lev-
els were evaluated (Table 1), only sponge weight was significantly
associated with oral IgG (LCR: −0.72, 95% CI, −0.86 to −0.59)
and oral IgA levels (LCR: −0.54; 95% CI, −0.66 to −0.42).
Although not statistically significant, we did observe that oral IgG
and IgA levels were elevated in specimens which hemoglobin was
detectable by our Hemastix strip test (Table 1).
DISCUSSION
Saliva represents a potential alternative sample collection method
for immune monitoring studies. This could simplify efforts to
monitor the long-term immunological impact of vaccines such as
the recently approved prophylactic HPV vaccines. However, it is
still unknown whether saliva levels of antibodies reflect local lev-
els at the cervix. In this study, we evaluated whether total oral Ig
measures were good proxies for genital tract Ig levels. The aims
were to (1) directly compare Ig levels measured in the oral cavity
against those measured at the cervix and (2) examine whether fac-
tors previously found to affect levels of Ig at the cervix were also
associated with oral Ig levels.
We showed that IgG and IgA in oral secretions are lower than
levels found in the cervix and not reflective of IgG or IgA levels in
the cervix. The overall levels of oral IgG and IgA reported here are
in agreement with other studies (Norhagen et al., 1989; Tamashiro
and Constantine, 1994; Engstrom et al., 1996; Kozlowski et al.,
1999), and the levels of oral IgG and IgA suggest that the collec-
tion device in our study absorbed whole saliva, which consists of all
oral mucosa products. Furthermore, these results suggest that our
collection and storage method preserved immunoglobulins even
though oral fluid contains enzymes capable of degrading proteins
such as immunoglobulins.
We examined the association of oral IgG and IgA with men-
strual cycle and hormonal contraceptive use. Oral IgG and IgA
levels were not affected by phase of menstrual cycle or by oral
contraceptive use. These observations, while consistent with pre-
viously reported findings for plasma levels (Safaeian et al., 2009b),
contrast with the reported strong effect of menstrual cycle and
oral contraceptive use on cervical Ig levels (Safaeian et al., 2009a),
further reinforcing the need for caution when using oral Ig mea-
surements to reflect levels at the cervix. Although our study did not
directly measure antigen-specific vaccine-induced antibody levels,
our results suggest caution in using oral specimens to monitor
long-term impact of vaccination programs such as the recently
approved HPV vaccine.
The only statistically significant correlate of oral IgG and IgA
we identified was oral sponge collection weight. The increased IgG
and IgA levels among lighter weight sponges suggests that the cal-
culated dilution factor may artificially increase the concentration
of oral IgG and IgA when low levels of fluid are obtained.
Previous studies have shown that there was modest to high cor-
relation between cervical and plasma anti-HPV16 levels (Nardelli-
Haefliger et al., 2003; Kemp et al., 2008); however, this was shown
to be the case among individuals who received the HPV vac-
cine only when menstrual cycle fluctuations were controlled by
oral contraceptive use (Nardelli-Haefliger et al., 2003). Although
antigen-specific responses have been reported to be detected in
oral fluid from vaccine recipients (Rowhani-Rahbar et al., 2009),
it is still unclear whether such responses would correlate with levels
observed at the cervix among naturally cycling women.
FIGURE 3 | Comparison of IgG and IgA levels between oral and
cervical specimens. Matching oral and cervical secretion samples from
the three phases of the menstrual cycle from 85 participants were
measured for IgG and IgA levels. The scatter plots of oral-cervix IgG (A)
and IgA (B) levels are plotted based on untransformed values and include
the three phases of the menstrual cycle from each participant. A p-value
<0.05 was considered significant, and LRC stands for Linear Regression
Coefficient.
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Table 1 | Association between covariates of interest and oral IgG and IgA (µg/ml) levels.
IgG (µg/ml) IgG IgA (µg/ml) IgA
N GMTa LRC (95% CI)b GMTa LRC (95% CI)b
Oral Igd 255 19.6 101.3
Cervix Igd 255 566.7 0.01 (−0.05 to 0.07) 268.6 0.02 (−0.04 to 0.08)
Plasma Igd 255 8204.5 0.74 (0.12 to 1.35) 2030.1 −0.03 (−0.32 to 0.25)
AGE
27–30 84 22 −0.05 (−0.11 to 0.01)c 98.5 0.01 (−0.04 to 0.06)c
31–33 96 19.4 101.0
34–35 75 17.4 105.0
ORAL COLLECTION SPONGE WEIGHT
>0.21 g 130 12.9 Reference 74.9 Reference
<0.21 g 125 30.1 −0.72 (−0.86 to −0.59) 138.6 −0.54 (−0.66 to −0.42)
HEMOGLOBIN IN ORAL SECRETIONS
Negative 21 17.2 Reference 95.6 Reference
Trace 184 17.3 −0.09 (−0.44 to 0.26) 97.2 −0.04 (−0.34 to 0.26)
Positive 50 32.2 0.23 (−0.17 to 0.62) 120.7 0.10 (−0.23 to 0.43)
CURRENT OC USE
No 191 19.3 Reference 98.6 Reference
Yes 44 18.0 0.01 (−0.31 to 0.34) 104.2 0.06 (−0.2 to 0.32)
HPV INFECTION
No 207 19.5 Reference 102.1 Reference
Yes 42 18.5 −0.05 (−0.44 to 0.34) 95.1 −0.08 (−0.38 to 0.23)
PARITY
0 30 19.8 Reference 124.4 Reference
1–3 162 17.5 −0.12 (−0.57 to 0.33) 91.6 −0.30 (−0.65 to 0.04)
≥4 63 25.7 0.27 (−0.23 to 0.77) 119.1 −0.04 (−0.43 to 0.35)
CURRENT ILLNESS
No 174 19.9 Reference 101.6 Reference
Yes 81 18.9 −0.02 (−0.19 to 0.15) 100.6 0.02 (−0.13 to 0.16)
CURRENT SMOKER
No 228 19.1 Reference 97.6 Reference
Yes 27 23.5 0.22 (−0.25 to 0.69) 139.1 0.35 (−0.01 to 0.72)
aGeometric mean values of IgG and IgA are based on log transformed values which have been transformed back to the original measurements.
bThe Generalized Estimation Equation (GEE) model was used to evaluate the associations between the listed covariates and log transformed oral IgG and IgA values.
The Linear Regression Coefficient (LRC) values are presented along with 95% CIs.
cAge entered as a continuous variable in the model.
dThe immunoglobulin measures presented reflect the geometric mean of all samples regardless of the menstrual cycle.
Bold text represents an LRC being significant at p<0.05.
In conclusion, our data suggest that oral IgG and IgA are
not a good surrogate for total IgG and IgA measures in cer-
vical secretions. Future studies will need to assess whether
antigen-specific antibody responses in oral samples obtained
from vaccinees may better reflect levels observed in cervix before
such markers can be used as an alternative to cervical secre-
tion measures when monitoring local antigen-specific humoral
responses.
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